INCYTE CORP·4

Jul 20, 4:09 PM ET

Issa Mohamed Khairie 4

4 · INCYTE CORP · Filed Jul 20, 2026

Research Summary

AI-generated summary of this filing

Updated

Incyte (INCY) EVP Mohamed Khairie Receives Awards, Sells 1,093 Shares

What Happened Mohamed Khairie, EVP and Head of U.S. Commercial at Incyte (INCY), sold 1,093 shares in an open-market sale on July 16, 2026 for $115.01 per share, generating $125,706. On the same day he received multiple equity awards: 7,857 restricted stock units (RSUs), 19,643 performance-share units (derivative), and 33,918 option-related derivative awards (all reported as grants at $0.00 acquisition price in the Form 4).

These awards are compensation grants (not purchases). The cash-generating action was the modest open-market sale; the larger numeric amounts shown on the filing are awards that will vest or pay out in the future, subject to service and performance conditions.

Key Details

  • Transaction date: July 16, 2026 (Form 4 filed July 20, 2026; filing marked late).
  • Sale: 1,093 shares sold at $115.01 each; total proceeds $125,706.
  • Grants on July 16, 2026:
    • 7,857 RSUs (F1) — settle 1-for-1 for common stock; vest 25% each year over 4 years.
    • 19,643 performance-share units (F3) — represent rights to receive up to 200% of one share each, earned based on relative total shareholder return over a 3-year performance period; earned shares vest on the 3rd anniversary, subject to continued service.
    • 33,918 derivative awards (options) (F4) — options vest in 37 installments: 25% after one year, remainder monthly over three years.
  • Aggregate outstanding unvested RSUs: filing notes 71,797 shares issuable under previously reported unvested RSUs including the July 16 grant (F2).
  • Shares owned after transaction: not specified in the provided filing data.
  • Filing timeliness: marked late (filed 4 days after the transactions); late filings reduce near-term transparency but do not change the underlying transactions.

Context

  • The sale was a routine open-market disposition; such sales are common for liquidity or tax reasons and do not by themselves indicate a change in insider sentiment.
  • The RSUs, performance shares and options are compensation awards and will only result in actual shares (or value) if vesting/performance conditions are met.
  • Performance-share awards can pay out up to 200% of target depending on relative TSR vs. peers; options vest over time so they are a retention incentive rather than immediate stock ownership.

Insider Transaction Report

Form 4
Period: 2026-07-16
Issa Mohamed Khairie
EVP, Head of U.S. Commercial
Transactions
  • Sale

    Common Stock

    2026-07-16$115.01/sh1,093$125,70663,940 total
  • Award

    Common Stock

    [F1][F2]
    2026-07-16+7,85771,797 total
  • Award

    Performance Shares

    [F3]
    2026-07-16+19,64319,643 total
    Exp: 2029-07-16Common Stock (19,643 underlying)
  • Award

    Employee Stock Option (right to buy)

    [F4]
    2026-07-16+33,91833,918 total
    Exercise: $116.65Exp: 2036-07-15Common Stock (33,918 underlying)
Footnotes (4)
  • [F1]Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.
  • [F2]Including the July 16, 2026 grant, this includes an aggregate of 71,797 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
  • [F3]Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.
  • [F4]The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks:
Signature
/s/ Elizabeth Feeney, Attorney-In-Fact|2026-07-20

Documents

1 file
  • 4
    wk-form4_1784578149.xmlPrimary

    FORM 4